Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Jul 13, 2020 9:27am

243 Views

Post# 31259498

RE:RE:RE:RE:200,000 shares

Yes they are well aware of that. The issue is trading well on the nasdaq once you've uplisted. Thats what theyre working on now. In addition to the economic report on US/Euro/Jap markets for NSAIDS (i.e. doing the market analysts' job for them) and the FDA meeting in november.

If you watch the video carefully, Dan notes that hes trying to expidite the meeting to August.

Benedict16th wrote: The need to list the stock on Nasdaq to make ATE fly like an eagle. Do the reverse 10/1 and let's move on. Canada is a great country but not for great risk/reward takers

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide